Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21249161 | 0.91 | FOLH1 (0.74) | FOLH1 | |
| SCHEMBL29340071 | 0.91 | FOLH1 (0.74) | FOLH1 | |
| SCHEMBL17705986 | 0.90 | FOLH1 (0.76) | FOLH1 | |
| SCHEMBL24123178 | 0.90 | FOLH1 (0.73) | FOLH1 | |
| SCHEMBL19303442 | 0.89 | FOLH1 (0.72) | FOLH1 | |
| SCHEMBL29678976 | 0.88 | FOLH1 (0.71) | FOLH1 | |
| SCHEMBL29678975 | 0.88 | FOLH1 (0.71) | FOLH1 | |
| SCHEMBL29679449 | 0.88 | FOLH1 (0.72) | FOLH1 | |
| SCHEMBL19296400 | 0.87 | FOLH1 (0.70) | FOLH1 | |
| SCHEMBL19296390 | 0.87 | FOLH1 (0.70) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | TELIX PHARMACEUTICALS INNOVATIONS PTY LTD (AU) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | KLK3, FOLH1, CA14 | FOLH1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.